Vaxil Launches Manufacturing of ImMucin Immunotherapy for Future Trials

Vaxil (TSXV:VXL) entered an agreement with BCN Peptides for the cGMP manufacturing of its lead product VXL100/ImMucin.
As quoted in the press release:

This new batch is intended for use in the Company’s upcoming clinical trials including multiple myeloma and/or solid tumor indications. The Company is targeting completion of manufacturing for late Q4 2017 to early Q1 2018.

BCN Peptides, based in Spain, is an expert manufacturer of generic and custom-made peptides in various scales, from R&D all the way to commercial batches. BCN Peptides successfully produced the previous batch of VXL100 for Vaxil utilizing its improved process with high yields, which was effectively utilized in preclinical development.

Dr. Limor Chen, VP Operations and Clinical Development, added: “We are very pleased to launch manufacturing of a new batch of ImMucin™ in collaboration with BCN Peptides, our long-term partner with a proven track record. This is a major step towards our first clinical trial under IND and significantly facilitates our development plan.”

Click here to read the full press release.

Source: www.marketwired.com